TCS-PIM-1-4a

Research use only, not for human use.

(Z)-SMI-4a is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.

SMI-4a is a potent and selective Pim protein kinase inhibitor, which blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells. SMI-4a may be developed as a therapeutic strategy for the treatment of pre-T-LBL.

Western Blot Analysis Cell Line:HEK-293T cells Concentration:0.5 μM Incubation Time:1 hour Result:Caused a dose-dependent reduction in Pim-1-induced 4E-BP1 phosphorylation, with an IC50 of approximately 125 nM.

——

SMI-4a | SMI4a | SMI 4a | TCS PIM-1 4a.

GPCR/G Protein

Antibacterial

Pim1

Cancer

——

438190-29-5

273.23

C11H6F3NO2S

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (365.99 mM)

c1cc(cc(c1)C(F)(F)F)/C=C\1/C(=O)NC(=O)S1

5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione

(-20℃)

With Ice Pack

≥ 2 years